Auricular point comprehensive therapy for insomnia in chronic kidney diseases patients: a randomized control study

注册号:

Registration number:

ITMCTR2200006832

最近更新日期:

Date of Last Refreshed on:

2022-11-27

注册时间:

Date of Registration:

2022-11-27

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

耳穴综合疗法治疗慢性肾脏病失眠患者的随机对照研究

Public title:

Auricular point comprehensive therapy for insomnia in chronic kidney diseases patients: a randomized control study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

耳穴综合疗法治疗慢性肾脏病失眠患者的随机对照研究

Scientific title:

Auricular point comprehensive therapy for insomnia in chronic kidney diseases patients: a randomized control study

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2200066190 ; ChiMCTR2200006832

申请注册联系人:

雷诺

研究负责人:

吴一帆

Applicant:

Lei Nuo

Study leader:

Wu Yifan

申请注册联系人电话:

Applicant telephone:

+86 13538860722

研究负责人电话:

Study leader's telephone:

+86 13560324448

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

373489077@qq.com

研究负责人电子邮件:

Study leader's E-mail:

wuyifan007@gzucm.edu.cn

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

广东省广州市白云区机场路12号

研究负责人通讯地址:

广东省广州市越秀区大德路111号

Applicant address:

12 Jichang Road, Baiyun District, Guangzhou, Guangdong, China

Study leader's address:

111 Dade Road, Yuexiu District, Guangzhou, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

广州中医药大学第二临床医学院

Applicant's institution:

The Second Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, China

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

YF2022-015-01

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

广东省中医院伦理委员会

Name of the ethic committee:

Ethics Committee of Guangdong Provincial Hospital of Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2022/3/24 0:00:00

伦理委员会联系人:

李晓彦

Contact Name of the ethic committee:

Li Xiaoyan

伦理委员会联系地址:

广州市越秀区大德路111号研修楼1912

Contact Address of the ethic committee:

111 Dade Road, Yuexiu District, Guangzhou, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 20 81887233 35943

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

广州中医药大学第二附属医院(广东省中医院)

Primary sponsor:

The Second Affiliated Hospital of Guangzhou University of Chinese Medicine(Guangdong Provincial Hospital of Chinese Medicine)

研究实施负责(组长)单位地址:

广东省广州市越秀区大德路111号

Primary sponsor's address:

111 Dade Road, Yuexiu District, Guangzhou, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东省

市(区县):

广州市

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

广州中医药大学第二附属医院(广东省中医院)

具体地址:

广东省广州市越秀区大德路111号

Institution
hospital:

The Second Affiliated Hospital of Guangzhou University of Chinese Medicine(Guangdong Provincial Hospital of Chinese Medicine)

Address:

111 Dade Road, Yuexiu District, Guangzhou, China

经费或物资来源:

研究生经费/课题经费

Source(s) of funding:

Postgraduate funding / subject funding

研究疾病:

慢性肾脏病、慢性失眠

研究疾病代码:

Target disease:

chronic kidney diseases, chronic insomnia

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

探索耳穴综合疗法对慢性肾脏病3-5期非透析失眠患者睡眠情况及其他临床指标的影响。

Objectives of Study:

To explore the effects of auricular point comprehensive therapy on sleep quality and clinical indicators of chronic insomnia patients with stage 3-5, non-dialysis chronic kidney disease.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

①符合KDIGO 指南中 CKD 的诊断标准且临床分期为1-5期的患者; ②符合ICSD-3慢性失眠诊断标准的患者; ③匹兹堡睡眠质量指数(PSQI)量表评分>5分的患者; ④年龄18-75岁的患者; ⑤具有一定的阅读理解能力,能配合使用智能手机、手环等电子产品的患者; ⑥既往未使用任何辅助睡眠的西药或已停药1周者; ⑦已签署知情同意书的患者。

Inclusion criteria

①Stage 1-5 Chronic kidney diseases patients diagnosed according to the KDIGO 2012 Clinical Practice Guideline. ②Chronic insomnia diagnosed according to the International Classification of Sleep Disorders, Third Edition. ③Baseline global PSQI score > 5. ④Age between 18 ~ 75 years old. ⑤Patients with normal reading and comprehension ability, who can use electronic products such as smart phone and wristband. ⑥Patients who have not used any sleeping pills before or have drug withdrawal for at least 1 week. ⑦Informed consent.

排除标准:

①妊娠或哺乳期妇女; ②近期疾病处于急性期患者; ③患有严重的呼吸系统疾病的患者; ④已行肾脏替代治疗的患者,包括维持性血液透析、腹膜透析及肾移植; ⑤在入组前3个月内有耳穴疗法治疗史的患者; ⑥外耳局部存在脓肿、溃破、冻疮、湿疹,或存在皮肤过敏、凝血功能障碍等耳穴综合疗法禁忌症的患者; ⑦对刮痧油或耳穴贴胶布过敏的患者; ⑧存在其他导致失眠的因素的患者,如疼痛、皮肤瘙痒、睡眠呼吸暂停、不宁腿综合征等; ⑨因其他原因无法配合的患者。

Exclusion criteria:

①Currently pregnant or lactating. ②Present of acute medical condition. ③Patients with severe respiratory problems. ④Having received renal replacement therapy, including maintenance hemodialysis, peritoneal dialysis and kidney transplantation. ⑤Having received auricular acupressure therapy in the previous 3 months before enrollment. ⑥Contraindication of auricular point comprehensive therapy (e.g., local abscess, ulceration, frostbite and eczema of external ear, presence of skin allergy, or coagulation dysfunction). ⑦Patients who are allergic to scraping oil or ear sticking tape. ⑧Insomnia caused by other medical condition, (e.g., pain, itchy skin, sleep apnea syndrome, or restless leg syndrome). ⑨Unable to cooperate due to other reasons.

研究实施时间:

Study execute time:

From 2022-03-01

To      2023-03-31

征募观察对象时间:

Recruiting time:

From 2022-12-01

To      2023-01-31

干预措施:

Interventions:

组别:

假耳穴组

样本量:

22

Group:

Sham auricular acupressure group

Sample size:

干预措施:

假耳穴疗法

干预措施代码:

Intervention:

Sham auricular acupressure therapy

Intervention code:

组别:

耳穴组

样本量:

22

Group:

Auricular acupressure group

Sample size:

干预措施:

耳穴压豆疗法

干预措施代码:

Intervention:

Auricular acupressure therapy

Intervention code:

组别:

综合疗法组

样本量:

22

Group:

Comprehensive therapy group

Sample size:

干预措施:

耳穴综合疗法

干预措施代码:

Intervention:

Auricular point comprehensive therapy

Intervention code:

样本总量 Total sample size : 66

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

广东

市(区县):

广州

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

广州中医药大学第二附属医院(广东省中医院

单位级别:

三级甲等医院

Institution/hospital:

The Second Affiliated Hospital of Guangzhou University of Chinese Medicine(Guangdong Provincial Hospital of Chinese Medicine)

Level of the institution:

Tertiary A hospital

测量指标:

Outcomes:

指标中文名:

中医证候评分

指标类型:

次要指标

Outcome:

Chinese medicine symptom complex score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生化指标

指标类型:

次要指标

Outcome:

Biochemical Indicators

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

华为荣耀智能手环记录的客观睡眠质量指数

指标类型:

次要指标

Outcome:

Objective sleep quality index recorded by Huawei Honor smart bracelet

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血压

指标类型:

次要指标

Outcome:

blood pressure

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

匹兹堡睡眠质量指数

指标类型:

主要指标

Outcome:

Pittsburgh Sleep Quality Index

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

尿液

组织:

Sample Name:

urine

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 18
Min age years
最大 75
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

由团队中不参与本研究的研究者使用SPSS 21.0软件的随机函数对患者分配治疗关联编号和入组顺序号

Randomization Procedure (please state who generates the random number sequence and by what method):

Random functions of SPSS 21.0 software were used by team members not involved in this study to assign patients with treatment association numbers and enrollment sequence numbers.

盲法:

单盲

Blinding:

single-blind

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

毕业时归档广州中医药大学研究生院

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Archiving Guangzhou University of Chinese Medicine after graduation

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

1,用病例报告表收集原始数据; 2.病例资料保存在广东省中医院的电子病例系统。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

1. Original data are collected using a Case Report Form. 2. Medical records are stored in the electronic medical records system of Guangdong Provincial Hospital of Chinese Medicine.

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above